Clinical trial · no report yet · Phase 3
NCT05239728
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
- NCT05239728 ↗
- Active not recruiting
- Merck Sharp & Dohme LLC
- 138 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 94 | |
| YouTube | 19 | |
| Podcasts | 19 | |
| X videos | 6 |
The trial
ClinicalTrials.gov- Official title
- A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Belzutifan; Pembrolizumab; Placebo
- Arms
- Belzutifan + Pembrolizumab · Experimental
- Placebo + Pembrolizumab · Experimental
- Enrollment
- 1,800 (estimated)
- Primary outcomes
- Disease-Free Survival (DFS)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Mar 15, 2022
- Primary completion
- Oct 28, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05239728 · updated May 15, 2026
Publications
linked from the registry- Choueiri TK, Motzer RJ, Karam JA, Yip W, Suarez C, Ye D, He Z, Caglevic C, Ferguson T, Chang YH, Rojas C, Iacovelli R, Urun Y, Verzoni E, Vazquez Limon JC, Porta C, Uzzo RG, Lee JL, Venugopal B, McKay RR, Hammers H, Miyake H, Chahoud J, Liu H, Burgents JE, Sharma M, Powles TB; LITESPARK-022 Investigators. Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma. N Engl J Med. 2026 Jul 2;395(1):32-43. doi: 10.1056/NEJMoa2518245. PubMed 42384869